Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunosuppressive Agents Clear all
Completed No phase listed Observational

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

NCT00116090
View directory record Official record
Conditions
Uveitis, Cancer, Infection, Mortality, Immunosuppression
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
6,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Baltimore, Maryland • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

NCT00260689
View directory record Official record
Conditions
Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
Interventions
Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine, Alemtuzumab
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Phase 2 Interventional

Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia

NCT00061360
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
ATG+Rapamune+cyclosporine, ATG+cyclosporine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 110 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients

NCT00922883
View directory record Official record
Conditions
Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Results available

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

NCT00296296
View directory record Official record
Conditions
Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Cyclosporin, Tacrolimus, 'Diabetes Education / Management'
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Phase 2 Interventional

Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults

NCT00001637
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Leukemia, Myelodysplastic Syndrome, Myeloid Leukemia
Interventions
Blood cell transplantation
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
55 Years to 71 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome

NCT00604201
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA)
Interventions
Umbilical Cord Blood
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 2, 2026, 9:28 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 2, 2026, 9:28 PM EDT
Completed No phase listed Observational

Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy

NCT04436380
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression

NCT01733056
View directory record Official record
Conditions
Immunosuppression
Interventions
Flu Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 2, 2026, 9:28 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

NCT01856257
View directory record Official record
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 2, 2026, 9:28 PM EDT
Recruiting Phase 2Phase 3 Interventional

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889
View directory record Official record
Conditions
Myasthenia Gravis, Generalized Myasthenia Gravis
Interventions
Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101
Drug · Biological
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 2, 2026, 9:28 PM EDT
Terminated Phase 2 Interventional Results available

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

NCT01279616
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Fludarabine monophosphate, Rituximab, Busulfan, ATG, Cyclophosphamide, Mycophenolate mofetil, Tacrolimus
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 9:28 PM EDT
Terminated Phase 3 Interventional

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

NCT03995901
View directory record Official record
Conditions
Transplanted Organ Rejection
Interventions
FCR001
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 2, 2026, 9:28 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

NCT05436418
View directory record Official record
Conditions
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
Interventions
Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Duarte, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Not applicable Interventional

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

NCT05542381
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Loteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]
Drug · Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Early Phase 1 Interventional Results available

Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus

NCT04233164
View directory record Official record
Conditions
Systemic Lupus Erythematous (SLE)
Interventions
Solu-Medrol 1mg/kg, Solu-Medrol 250 mg
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 2, 2026, 9:28 PM EDT
Completed No phase listed Observational

A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia

NCT07415083
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 2, 2026, 9:28 PM EDT
Completed No phase listed Observational

Microsampling Assays for Immunosuppressive Drugs in Children

NCT04989686
View directory record Official record
Conditions
Immunosuppression
Interventions
Microsampling
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 17 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 2, 2026, 9:28 PM EDT
Recruiting Phase 3 Interventional

Abatacept for the Treatment of Giant Cell Arteritis

NCT04474847
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 2, 2026, 9:28 PM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

NCT00089141
View directory record Official record
Conditions
Cancer
Interventions
mycophenolate mofetil, placebo
Drug
Lead sponsor
Martin, Paul
Other
Eligibility
4 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Phase 2 Interventional

A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome

NCT00001839
View directory record Official record
Conditions
Hematologic Diseases, Myelodysplastic Syndromes
Interventions
Antithymocyte globulin, Cyclosporine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 9:28 PM EDT
Withdrawn No phase listed Observational

Observational Registry Study of Renal Transplant Patients

NCT01284257
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Springfield, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 2, 2026, 9:28 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

NCT01256294
View directory record Official record
Conditions
Renal Transplant
Interventions
Generic Tacrolimus, Branded Tacrolimus
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 2, 2026, 9:28 PM EDT